Claude C Schulman1. 1. University Clinics of Brussels, Hôpital Erasme, Department of Urology, Route de Lennik 808, 1070 Brussels, Belgium. Claude.Schulman@ulb.ac.be
Abstract
BACKGROUND: Tamsulosin MR has been on the market for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) for many years. Recently, tamsulosin OCAS was introduced, which has improved pharmacokinetics. OBJECTIVE: To evaluate the efficacy and safety of tamsulosin. METHODS: Literature was identified through a PubMed search using the term 'tamsulosin' and by screening reference lists of review articles. RESULTS: Tamsulosin rapidly improves LUTS/BPH, with benefits maintained in the long-term. The overall tolerability of tamsulosin MR 0.4 mg is comparable to that of placebo. While the efficacy of tamsulosin OCAS and MR is comparable, tamsulosin OCAS is slightly better tolerated. CONCLUSION: Tamsulosin OCAS 0.4 mg has a favourable efficacy/safety profile and should be considered the treatment of choice for patients requiring optimal symptom control without increasing the risk of cardiovascular adverse events.
BACKGROUND:Tamsulosin MR has been on the market for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) for many years. Recently, tamsulosinOCAS was introduced, which has improved pharmacokinetics. OBJECTIVE: To evaluate the efficacy and safety of tamsulosin. METHODS: Literature was identified through a PubMed search using the term 'tamsulosin' and by screening reference lists of review articles. RESULTS:Tamsulosin rapidly improves LUTS/BPH, with benefits maintained in the long-term. The overall tolerability of tamsulosin MR 0.4 mg is comparable to that of placebo. While the efficacy of tamsulosinOCAS and MR is comparable, tamsulosinOCAS is slightly better tolerated. CONCLUSION:TamsulosinOCAS 0.4 mg has a favourable efficacy/safety profile and should be considered the treatment of choice for patients requiring optimal symptom control without increasing the risk of cardiovascular adverse events.